Claret Asset Management Corp Sells 136 Shares of Johnson & Johnson (NYSE:JNJ)

Claret Asset Management Corp lessened its holdings in shares of Johnson & Johnson (NYSE:JNJFree Report) by 0.2% in the third quarter, according to its most recent filing with the SEC. The firm owned 63,243 shares of the company’s stock after selling 136 shares during the period. Johnson & Johnson accounts for 1.9% of Claret Asset Management Corp’s portfolio, making the stock its 15th largest position. Claret Asset Management Corp’s holdings in Johnson & Johnson were worth $9,850,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Moneta Group Investment Advisors LLC lifted its position in Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after buying an additional 54,326,454 shares in the last quarter. Norges Bank acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $4,609,399,000. Capital International Investors boosted its position in Johnson & Johnson by 62.7% during the second quarter. Capital International Investors now owns 27,825,795 shares of the company’s stock valued at $4,605,627,000 after purchasing an additional 10,724,110 shares during the last quarter. Journey Strategic Wealth LLC increased its position in shares of Johnson & Johnson by 161,420.2% during the 2nd quarter. Journey Strategic Wealth LLC now owns 7,276,483 shares of the company’s stock worth $1,204,404,000 after purchasing an additional 7,271,978 shares during the last quarter. Finally, Morgan Stanley raised its stake in shares of Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after purchasing an additional 4,521,062 shares in the last quarter. 68.40% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on JNJ. Raymond James increased their price target on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. UBS Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $167.00 to $180.00 in a report on Friday, December 1st. TheStreet lowered Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, November 17th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Finally, Morgan Stanley cut their price target on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. Eight investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $176.14.

Check Out Our Latest Research Report on JNJ

Johnson & Johnson Trading Up 0.5 %

Shares of JNJ opened at $158.68 on Thursday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.96 and a current ratio of 1.16. Johnson & Johnson has a 52-week low of $144.95 and a 52-week high of $175.97. The firm has a market cap of $382.22 billion, a price-to-earnings ratio of 11.49, a PEG ratio of 2.65 and a beta of 0.53. The business’s fifty day moving average is $158.36 and its 200-day moving average is $158.07.

Johnson & Johnson (NYSE:JNJGet Free Report) last issued its earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The firm had revenue of $21.40 billion during the quarter, compared to the consensus estimate of $21.02 billion. During the same quarter in the previous year, the firm earned $2.35 earnings per share. The business’s quarterly revenue was down 9.7% on a year-over-year basis. Equities analysts anticipate that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be issued a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 3.00%. The ex-dividend date is Friday, February 16th. Johnson & Johnson’s dividend payout ratio (DPR) is 34.47%.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 59,397 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.20% of the company’s stock.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.